Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Spyre Therapeutics, Inc.
13D/A
Amendment 8
SYRE · 00773J202
|
10.0% |
10/9/2026
Event 10/7/2026
|
|||
| Fairmount Funds Management LLC | 9.2% | ||||
| Fairmount Healthcare Fund II L.P. | 9.2% | ||||
| Harwin Peter Evan | 10.0% | ||||
| Kiselak Tomas | 10.0% | ||||
|
Korsana Biosciences, Inc.
13D
KRSA · 23255M303
|
20.0% |
9/11/2026
Event 9/8/2026
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 15.2% | ||||
| Fairmount Healthcare Co-Invest VI L.P. | 4.8% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Apogee Therapeutics, Inc.
13D/A
Amendment 7
APGE · 03770N101
|
0% |
9/3/2026
Event 9/3/2026
|
|||
| Fairmount Funds Management LLC | 0% | ||||
| Fairmount Healthcare Fund II L.P. | 0% | ||||
| Peter Evan Harwin | 0% | ||||
| Tomas Kiselak | 0% | ||||
|
Crescent Biopharma, Inc.
13D/A
Amendment 2
CBIO · G2545C104
|
16.5% |
7/20/2026
Event 7/16/2026
|
|||
| Fairmount Funds Management LLC | 16.5% | ||||
| Fairmount Healthcare Fund II L.P. | 16.5% | ||||
| Peter Harwin | 16.5% | ||||
| Tomas Kiselak | 16.5% | ||||
|
Oruka Therapeutics, Inc.
13D/A
Amendment 6
ORKA · 687604108
|
19.5% |
7/1/2026
Event 7/1/2026
|
|||
| Fairmount Funds Management LLC | 19.5% | ||||
| Fairmount Healthcare Fund II L.P. | 16.0% | ||||
| Fairmount Healthcare Co-Invest III L.P. | 4.0% | ||||
| Harwin Peter Evan | 19.5% | ||||
| Kiselak Tomas | 19.5% | ||||
|
Spyre Therapeutics, Inc.
13D/A
Amendment 7
SYRE · 00773J202
|
10.0% |
6/23/2026
Event 6/23/2026
|
|||
| Fairmount Funds Management LLC | 9.2% | ||||
| Fairmount Healthcare Fund II L.P. | 9.2% | ||||
| Peter Evan Harwin | 10.0% | ||||
| Tomas Kiselak | 10.0% | ||||
|
Apogee Therapeutics, Inc.
13D/A
Amendment 6
APGE · 03770N101
|
10.0% |
6/23/2026
Event 6/18/2026
|
|||
| Fairmount Funds Management LLC | 9.8% | ||||
| Fairmount Healthcare Fund II L.P. | 9.8% | ||||
| Peter Evan Harwin | 10.0% | ||||
| Tomas Kiselak | 10.0% | ||||
|
Jade Biosciences, Inc.
13D/A
Amendment 2
JBIO · 008064206
|
20.0% |
6/9/2026
Event 6/5/2026
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 16.2% | ||||
| Fairmount Healthcare Co-Invest IV L.P. | 4.4% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Enliven Therapeutics, Inc.
13G/A
Amendment 5
ELVN · 29337E102
|
3.1% |
5/15/2026
Event 3/31/2026
|
|||
| Fairmount Funds Management LLC | 3.1% | ||||
| Fairmount Healthcare Fund II L.P. | 3.1% | ||||
| Peter Harwin | 3.1% | ||||
| Kiselak Tomas | 3.1% | ||||
|
Viridian Therapeutics, Inc.\DE
13D/A
Amendment 8
VRDN · 92790C104
|
14.0% |
5/13/2026
Event 5/11/2026
|
|||
| Fairmount Funds Management LLC | 14.0% | ||||
| Fairmount Healthcare Fund II GP LLC | 14.0% | ||||
|
Oruka Therapeutics, Inc.
13D/A
Amendment 5
ORKA · 687604108
|
20.0% |
5/4/2026
Event 4/30/2026
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 16.2% | ||||
| Fairmount Healthcare Co-Invest III L.P. | 4.4% | ||||
| Harwin Peter Evan | 20.0% | ||||
| Kiselak Tomas | 20.0% | ||||
|
Spyre Therapeutics, Inc.
13D/A
Amendment 6
SYRE · 00773J202
|
10.0% |
4/20/2026
Event 4/16/2026
|
|||
| Fairmount Funds Management LLC | 9.1% | ||||
| Fairmount Healthcare Fund II L.P. | 9.1% | ||||
| Peter Harwin | 10.0% | ||||
| Tomas Kiselak | 10.0% | ||||
|
Cogent Biosciences, Inc.
13D/A
Amendment 10
COGT · 19240Q201
|
8.6% |
3/31/2026
Event 3/31/2026
|
|||
| Fairmount Funds Management LLC | 8.6% | ||||
| Fairmount Healthcare Fund II GP LLC | 8.6% | ||||
|
Apogee Therapeutics, Inc.
13D/A
Amendment 5
APGE · 03770N101
|
10.0% |
3/27/2026
Event 3/26/2026
|
|||
| Fairmount Funds Management LLC | 9.8% | ||||
| Fairmount Healthcare Fund II L.P. | 9.8% | ||||
| Peter Evan Harwin | 10.0% | ||||
| Tomas Kiselak | 10.0% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
Amendment 2
IKT · 45719W205
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Fairmount Funds Management LLC | 9.9% | ||||
| Fairmount Healthcare Fund II L.P. | 9.9% | ||||
| Peter Harwin | 9.9% | ||||
| Tomas Kiselak | 9.9% | ||||
|
Galecto, Inc.
13D/A
Amendment 1
DMRA · 36322Q206
|
20.0% |
2/11/2026
Event 2/9/2026
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 13.3% | ||||
| Fairmount Healthcare Co-Invest V L.P. | 6.7% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Cogent Biosciences, Inc.
13D/A
Amendment 9
COGT · 19240Q201
|
9.9% |
1/22/2026
Event 1/22/2026
|
|||
| Fairmount Funds Management LLC | 9.9% | ||||
| Fairmount Healthcare Fund II GP LLC | 9.9% | ||||
|
Apogee Therapeutics, Inc.
13D/A
Amendment 4
APGE · 03770N101
|
10.0% |
1/22/2026
Event 1/22/2026
|
|||
| Fairmount Funds Management LLC | 9.8% | ||||
| Fairmount Healthcare Fund II L.P. | 9.8% | ||||
| Peter Evan Harwin | 10.0% | ||||
| Tomas Kiselak | 10.0% | ||||
|
Crescent Biopharma, Inc.
13D/A
Amendment 1
CBIO · G2545C104
|
18.5% |
12/8/2025
Event 12/4/2025
|
|||
| Fairmount Funds Management LLC | 18.5% | ||||
| Fairmount Healthcare Fund II L.P. | 18.5% | ||||
| Peter Evan Harwin | 18.5% | ||||
| Tomas Kiselak | 18.5% | ||||
|
Dianthus Therapeutics, Inc.
13D/A
Amendment 4
DNTH · 252828108
|
4.9% |
11/25/2025
Event 11/21/2025
|
|||
| Fairmount Funds Management LLC | 4.9% | ||||
| Fairmount Healthcare Fund II L.P. | 4.9% | ||||
| Peter Evan Harwin | 4.9% | ||||
| Tomas Kiselak | 4.9% | ||||
|
Galecto, Inc.
13D
DMRA · 36322Q206
|
20.0% |
11/17/2025
Event 11/10/2025
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 20.0% | ||||
| Fairmount Healthcare Co-Invest V L.P. | 20.0% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Cogent Biosciences, Inc.
13D/A
Amendment 8
COGT · 19240Q201
|
9.9% |
11/17/2025
Event 11/13/2025
|
|||
| Fairmount Funds Management LLC | 9.9% | ||||
| Fairmount Healthcare Fund II GP LLC | 9.9% | ||||
|
Viridian Therapeutics, Inc.\DE
13D/A
Amendment 7
VRDN · 92790C104
|
15.1% |
10/27/2025
Event 10/23/2025
|
|||
| Fairmount Funds Management LLC | 15.1% | ||||
| Fairmount Healthcare Fund II GP LLC | 15.1% | ||||
|
Spyre Therapeutics, Inc.
13D/A
Amendment 5
SYRE · 00773J202
|
10.0% |
10/17/2025
Event 10/15/2025
|
|||
| Fairmount Funds Management LLC | 9.0% | ||||
| Fairmount Healthcare Fund II L.P. | 9.0% | ||||
| Peter Evan Harwin | 10.0% | ||||
| Tomas Kiselak | 10.0% | ||||
|
Astria Therapeutics, Inc.
13G/A
Amendment 7
ATXS · 04635X102
|
4.0% |
10/15/2025
Event 10/14/2025
|
|||
| Fairmount Funds Management LLC | 4.0% | ||||
| Fairmount Healthcare Fund II GP LLC | 4.0% | ||||
|
Apogee Therapeutics, Inc.
13D/A
Amendment 3
APGE · 03770N101
|
10.0% |
10/14/2025
Event 10/10/2025
|
|||
| Fairmount Funds Management LLC | 9.8% | ||||
| Fairmount Healthcare Fund II L.P. | 9.8% | ||||
| Peter Evan Harwin | 10.0% | ||||
| Tomas Kiselak | 10.0% | ||||
|
Jade Biosciences, Inc.
13D/A
Amendment 1
JBIO · 008064206
|
20.0% |
10/8/2025
Event 10/6/2025
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 14.9% | ||||
| Fairmount Healthcare Co-Invest IV L.P. | 5.8% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Oruka Therapeutics, Inc.
13D/A
Amendment 4
ORKA · 687604108
|
20.0% |
9/19/2025
Event 9/17/2025
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 15.4% | ||||
| Fairmount Healthcare Co-Invest III L.P. | 5.3% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Dianthus Therapeutics, Inc. /DE/
13D/A
Amendment 3
DNTH · 252828108
|
9.9% |
9/15/2025
Event 9/11/2025
|
|||
| Fairmount Funds Management LLC | 9.9% | ||||
| Fairmount Healthcare Fund II L.P. | 9.9% | ||||
| Fairmount SPV III, LLC | 0% | ||||
| Peter Evan Harwin | 9.9% | ||||
| Tomas Kiselak | 9.9% | ||||
|
Enliven Therapeutics, Inc.
13G/A
Amendment 4
ELVN · 29337E102
|
6.3% |
8/14/2025
Event 6/30/2025
|
|||
| Fairmount Funds Management LLC | 6.3% | ||||
| Fairmount Healthcare Fund II L.P. | 6.3% | ||||
| Peter Harwin | 6.3% | ||||
| Tomas Kiselak | 6.3% | ||||
|
Cogent Biosciences, Inc.
13D/A
Amendment 7
COGT · 19240Q201
|
9.9% |
7/14/2025
Event 7/10/2025
|
|||
| Fairmount Funds Management LLC | 9.9% | ||||
| Fairmount Healthcare Fund II GP LLC | 9.9% | ||||
|
Crescent Biopharma, Inc.
13D
CBIO · G2545C104
|
20.0% |
6/23/2025
Event 6/13/2025
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 20.0% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Jade Biosciences, Inc.
13D
JBIO · 008064206
|
20.0% |
5/1/2025
Event 4/28/2025
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 12.7% | ||||
| Fairmount Healthcare Co-Invest IV L.P. | 8.2% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Oruka Therapeutics, Inc.
13D/A
Amendment 3
ORKA · 687604108
|
20.0% |
3/10/2025
Event 3/6/2025
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 14.0% | ||||
| Fairmount Healthcare Co-Invest III L.P. | 6.9% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Kiniksa Pharmaceuticals International, plc
13G/A
Amendment 3
KNSA · G52694109
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Fairmount Funds Management LLC | 0% | ||||
| Fairmount Healthcare Fund II L.P. | 0% | ||||
| Peter Harwin | 0% | ||||
| Tomas Kiselak | 0% | ||||
|
Anaptysbio, Inc.
13G/A
Amendment 1
ANAB · 032724106
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Fairmount Funds Management LLC | 0% | ||||
| Fairmount Healthcare Fund II L.P. | 0% | ||||
| Peter Harwin | 0% | ||||
| Tomas Kiselak | 0% | ||||
|
Astria Therapeutics, Inc.
13G/A
Amendment 6
ATXS · 04635X102
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
| Fairmount Funds Management LLC | 9.9% | ||||
| Fairmount Healthcare Fund II GP LLC | 9.9% | ||||
|
Enliven Therapeutics, Inc.
13G/A
Amendment 3
ELVN · 29337E102
|
6.6% |
2/14/2025
Event 12/31/2024
|
|||
| Fairmount Funds Management LLC | 6.6% | ||||
| Fairmount Healthcare Fund II L.P. | 6.6% | ||||
| Peter Harwin | 6.6% | ||||
| Tomas Kiselak | 6.6% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
Amendment 1
IKT · 45719W205
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
| Fairmount Funds Management LLC | 9.9% | ||||
| Fairmount Healthcare Fund II L.P. | 9.9% | ||||
| Peter Harwin | 9.9% | ||||
| Tomas Kiselak | 9.9% | ||||
|
Anaptysbio, Inc
13G
ANAB · 032724106
|
5.5% |
12/18/2024
Event 12/11/2024
|
|||
| Fairmount Funds Management LLC | 5.5% | ||||
| Fairmount Healthcare Fund II L.P. | 5.5% | ||||
| Peter Harwin | 5.5% | ||||
| Tomas Kiselak | 5.5% | ||||